Geron Corporation (NASDAQ:GERN) Receives $2.50 Average Target Price from Brokerages

Geron Corporation (NASDAQ:GERN) has earned a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $2.50.

Separately, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th.

Hedge Funds Weigh In On Geron

A number of large investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in shares of Geron by 68.9% in the 1st quarter. Bank of America Corp DE now owns 4,556,278 shares of the biopharmaceutical company’s stock worth $6,789,000 after buying an additional 1,858,268 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Geron by 826.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock worth $3,304,000 after buying an additional 1,978,839 shares during the period. Amundi lifted its holdings in shares of Geron by 365.7% in the 1st quarter. Amundi now owns 132,367 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 103,944 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Geron by 55.1% in the 1st quarter. California State Teachers Retirement System now owns 737,143 shares of the biopharmaceutical company’s stock worth $1,098,000 after buying an additional 261,886 shares during the period. Finally, Eversept Partners LP lifted its holdings in shares of Geron by 6.7% in the 1st quarter. Eversept Partners LP now owns 18,834,883 shares of the biopharmaceutical company’s stock worth $28,064,000 after buying an additional 1,174,900 shares during the period. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Price Performance

GERN opened at $1.14 on Friday. The business has a fifty day moving average of $1.44 and a 200 day moving average of $1.44. Geron has a 52-week low of $1.04 and a 52-week high of $2.01. The company has a quick ratio of 4.96, a current ratio of 6.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $728.13 million, a P/E ratio of -10.32 and a beta of 0.60.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The company had revenue of $51.84 million during the quarter, compared to analysts’ expectations of $50.59 million. As a group, sell-side analysts anticipate that Geron will post -0.02 EPS for the current year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.